With sales exceeding US$146 billion over the past decade, U.S. pharmaceutical giant Merck’s Keytruda has become the ...

Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of Britain's ...

Visa sees solid volume growth and cross-border gains, while Merck and Southern Company navigate competitive and regulatory ...

Merck & Co. Inc. is buying Cidara Therapeutics Inc. for $9.2 billion to acquire a late-stage flu candidate and also to outrace blockbuster Keytruda’s looming patent expiration. CD-388, Cidara’s lead ...

Merck buys Cidara for $9.2B to boost its pipeline ahead of Keytruda’s patent expiry. Cidara’s CD388 flu therapy in Phase 3 is the deal’s main growth driver. Pharma M&A heats up as major firms race to ...

Promega has scored an FDA green light for its microsatellite instability testing technology as a companion diagnostic for Merck and Eisai’s Keytruda-Lenvima combination for patients with advanced ...

Keytruda Qlex (pembrolizumab and berahydaluronidas alfa-pmph) is a prescription drug approved to treat different types of cancer, such as non-small cell lung cancer and head and neck cancer. Keytruda ...

As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its newly acquired PD-1xVEGF drug as a new cornerstone of ...

Pharmaceutical giant Merck has been prepping for the end of exclusivity for its leading drug. Verizon may not offer much in the way of growth, but it more than makes up for it with income. One of ...

President Donald Trump put pharmaceutical CEOs on notice, demanding they lower drug prices or he promised to get involved. He penned a letter to 17 CEOs in July, outlining what he wants from the ...